Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MPO | P05164 | 2/20 | 0.43 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.43 |
| ▸ | ELANE | P08246 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.31 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23217969 | 0.90 | MPO (0.46) | MPOOPRM1ALDH1A1CYP1A2CYP2C19 | |
| SCHEMBL23217970 | 0.90 | MPO (0.46) | MPOOPRM1ALDH1A1CYP1A2CYP2C19 | |
| SCHEMBL27102078 | 0.86 | MPO (0.45) | MPOOPRM1ALDH1A1CYP1A2CYP2C19 | |
| SCHEMBL27141256 | 0.84 | OPRM1 (0.37) | MPOOPRM1 | |
| SCHEMBL27141261 | 0.84 | OPRM1 (0.37) | MPOOPRM1 | |
| SCHEMBL23225676 | 0.83 | MPO (0.42) | MPOOPRM1ALDH1A1CYP1A2CYP2C19 | |
| SCHEMBL23217934 | 0.82 | OPRM1 (0.38) | MPOOPRM1ALDH1A1MEN1KMT2A | |
| SCHEMBL23217932 | 0.82 | OPRM1 (0.38) | MPOOPRM1ALDH1A1MEN1KMT2A | |
| SCHEMBL23225711 | 0.82 | OPRM1 (0.38) | MPOOPRM1ALDH1A1MEN1KMT2A | |
| SCHEMBL27102669 | 0.82 | MPO (0.48) | MPOOPRM1ALDH1A1CYP1A2CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240067651-A1 | PRODRUGS OF MYELOPEROXIDASE INHIBITORS | BIOHAVEN THERAPEUTICS LTD. | 2024-02-29 | — | — | US | disclosed |
| US-20240067651-A1 | PRODRUGS OF MYELOPEROXIDASE INHIBITORS | BIOHAVEN THERAPEUTICS LTD. | 2024-02-29 | — | — | US | disclosed |
| US-20240067651-A1 | PRODRUGS OF MYELOPEROXIDASE INHIBITORS | BIOHAVEN THERAPEUTICS LTD. | 2024-02-29 | — | — | US | disclosed |
| EP-4041735-A1 | PRODRUGS OF MYELOPEROXIDASE INHIBITORS | Biohaven Therapeutics Ltd. (US) | 2022-08-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240067651-A1 | PRODRUGS OF MYELOPEROXIDASE INHIBITORS | MPO, CAT, SOD1 | MPO 1/4885OPRM1 1161/4885ELANE 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.